Axcelead Drug Discovery Partners (Axcelead DDP, the group company of Axcelead), xFOREST Therapeutics Co., Ltd. (xFOREST) and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announce that the three companies have entered into a joint research agreement to discover multiple drugs that target RNA structures. Since 2020, Axcelead DDP and Kyowa Kirin started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform. With this agreement, we aim to construct a novel unparalleled platform for RNA-targeted small-molecule drug discovery. For details, please refer Axcelead DDP’s web-site (https://www.axcelead.com/en/news-release/5711/)